Risk of venous thromboembolism with bevacizumab in cancer patients.
Javier
J
Cortes
Cristina
C
Saura
Francesco
F
Atzori
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D012306:Risk; D054556:Venous Thromboembolism / Q000209:etiology*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab